[1]秦 菊,马云华,谢敏慧,等.慢性肾脏病5期非透析患者左心室肥厚危险因素分析[J].医学信息,2025,38(18):37-41.[doi:10.3969/j.issn.1006-1959.2025.18.008]
　QIN Ju,MA Yunhua,XIE Minhui,et al.Analysis of Risk Factors for Left Ventricular Hypertrophy in Non-dialysis Patientswith Stage 5 Chronic Kidney Disease[J].Journal of Medical Information,2025,38(18):37-41.[doi:10.3969/j.issn.1006-1959.2025.18.008]
点击复制

慢性肾脏病5期非透析患者左心室肥厚危险因素分析()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年18期
页码:
37-41
栏目:
论著
出版日期:
2025-09-15

文章信息/Info

Title:
Analysis of Risk Factors for Left Ventricular Hypertrophy in Non-dialysis Patientswith Stage 5 Chronic Kidney Disease
文章编号:
1006-1959（2025）18-0037-05
作者:
秦 菊1; 马云华1; 谢敏慧1; 阳文秀2; 邓 洁1; 欧 俊1; 廖雪玲1
桂林医科大学第一附属医院肾内科1，超声科2，广西 桂林 541000
Author(s):
QIN Ju1;  MA Yunhua1;  XIE Minhui1;  YANG Wenxiu2;  DENG Jie1;  OU Jun1;  LIAO Xueling1
Department of Nephrology1, Department of Ultrasound2, the First Affiliated Hospital of Guilin Medical University,Guilin 541000, Guangxi, China
关键词:
慢性肾脏病; 非透析; 左心室肥厚
Keywords:
Chronic kidney disease;  Non-dialysis;  Left ventricular hypertrophy
分类号:
R541
DOI:
10.3969/j.issn.1006-1959.2025.18.008
文献标志码:
A
摘要:
目的 探讨慢性肾脏脏病5期非透析（ND-CKD5）患者发生左心室肥厚（LVH）的危险因素，为预防ND-CKD5患者LVH发生提供依据。方法 纳入2022年2月-2023年3月于桂林医科大学第一附属医院肾内科就诊住院的255例ND-CKD5患者的临床资料，按照LVH发生情况分为LVH组与NLVH组，比较两组临床资料，采用多因素Logistic回归分析ND-CKD5期患者发生LVH的危险因素，并采用ROC曲线分析ND-CKD5患者发生LVH的预测指标。结果 纳入的255例ND-CKD5患者发生LVH 125例，发生率为49.02%。两组高血压病史、收缩压、Hb、Ca、P、BUN、胱抑素C、β2-MG、CK、D-二聚体、iPTH比较，差异有统计学意义（P＜0.05），而两组其余指标比较，差异无统计学意义（P＞0.05）；多因素Logistic回归分析显示，高血压病史、收缩压、Hb、β2-MG为ND-CKD5患者发生LVH的独立危险因素；ROC曲线分析显示，收缩压、Hb、β2-MG预测ND-CKD5患者发生LVH的ROC曲线下面积分别为0.601、0.622、0.657，而联合预测LVH的ROC曲线下面积为0.725，95%CI为0.663~0.788，敏感度为60.80%，特异度为76.15%。结论 LVH在ND-CKD5患者中的发生率高，且收缩压、Hb、β2-MG均是ND-CKD5患者LVH发生的独立危险因素，以上危险因素联合检测对预测LVH发生具有较好的临床价值。
Abstract:
Objective To investigate the risk factors of left ventricular hypertrophy (LVH) in non-dialysis patients with stage 5 chronic kidney disease (ND-CKD5), and to provide evidence for the prevention of LVH in patients with ND-CKD5. Methods The clinical data of 255 patients with ND-CKD5 admitted to the Department of Nephrology, the First Affiliated Hospital of Guilin Medical University from February 2022 to March 2023 were included. According to the occurrence of LVH, they were divided into LVH group and NLVH group. The clinical data of the two groups were compared. Multivariate logistic regression was used to analyze the risk factors of LVH in patients with ND-CKD5, and ROC curve was used to analyze the predictors of LVH in patients with ND-CKD5. Results Among the 255 patients with ND-CKD5, 125 had LVH, with an incidence of 49.02%. There were significant differences in the history of hypertension, systolic blood pressure, Hb, Ca, P, BUN, cystatin C, β2-MG, CK, D-dimer and iPTH between the two groups (P<0.05), there was no significant difference in the other indexes between the two groups (P>0.05). Multivariate Logistic regression analysis showed that history of hypertension, systolic blood pressure, Hb and β2-MG were independent risk factors for LVH in patients with ND-CKD5. ROC curve analysis showed that the area under the ROC curve of systolic blood pressure, Hb and β2-MG in predicting LVH in ND-CKD5 patients was 0.601, 0.622 and 0.657, respectively, while the area under the ROC curve of combined prediction of LVH was 0.725, 95%CI was 0.663-0.788, sensitivity was 60.80%, and specificity was 76.15%. Conclusion The incidence of LVH is high in patients with ND-CKD5, and systolic blood pressure, Hb and β2-MG are independent risk factors for LVH in patients with ND-CKD5. The combined detection of the above risk factors has good clinical value in predicting the occurrence of LVH.

参考文献/References:

[1]Wu Z,Shi M,Wang L,et al.Identification of Major Risk Factors and Non-linear Effects to the Development of Left Ventricular Hypertrophy in Chronic Kidney Disease by Constructing and Validation of Nomograms[J].Front Med (Lausanne),2022,9:914800.[2]Abiola BI,Raji YR,Ajayi S,et al.Comparative analysis of fibroblast growth Factor-23 as a correlate of cardiovascular disease among individuals with chronic kidney disease,hypertensives,and healthy controls[J].Niger J Clin Pract,2022,25(8):1247-1255.[3]Chisavu LA,Apostol A,Pop GN,et al.Exploring the relation between mortality and left ventricular structure and function in stable hemodialysis treated patients,a longitudinal multicenter cohort study[J].Sci Rep,2021,11(1):12694.[4]Zhao X,Zhu L,Jin W,et al.Echocardiographic left ventricular hypertrophy and geometry in Chinese chronic hemodialysis patients: the prevalence and determinants[J].BMC Cardiovasc Disord,2022,22(1):55.[5]Kim HM,Hwang IC,Choi HM,et al.Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension[J].Front Cardiovasc Med,2022,9:1082008.[6]孙宁玲,施仲伟,霍勇,等.高血压合并左心室肥厚诊治专家共识[J].中华心血管病杂志(网络版),2019,2(1):1-5.[7]Nubé MJ,Hoekstra T,Doganer V,et al.Left ventricular geometric patterns in end-stage kidney disease: Determinants and course over time[J].Hemodial Int,2018,22(3):359-368.[8]Ahmad FS,Cai X,Kunkel K,et al.CRIC Study Investigators.Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort[J].Am J Hypertens,2017,30(8):822-829.[9]Peterson GE,de Backer T,Gabriel A,et al.African American Study of Kidney Disease Investigators.Prevalence and correlates of left ventricular hypertrophy in the African American Study of Kidney Disease Cohort Study[J].Hypertension,2007,50(6):1033-1039.[10]Nitta K,Iimuro S,Imai E,et al.Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease[J].Clin Exp Nephrol,2013,17(5):730-742.[11]张哲,夏田雨,张晓林,等.非透析慢性肾脏病患者发生左心室肥厚的危险因素分析[J].临床肾脏病杂志,2019,19(2):107-111.[12]Maqbool S,Shafiq S,Ali S,et al.Left Ventricular Hypertrophy (LVH) and Left Ventricular Geometric Patterns in Patients with Chronic Kidney Disease (CKD) Stage 2-5 With Preserved Ejection Fraction (EF): A Systematic Review to Explore CKD Stage-wise LVH Patterns[J].Curr Probl Cardiol,2023,48(4):101590.[13]Cao X,Broughton ST,Waits GS,et al.Interrelations Between Hypertension and Electrocardiographic Left Ventricular Hypertrophy and Their Associations With Cardiovascular Mortality[J].Am J Cardiol,2019,123(2):274-283.[14]Hu J,Zhou Y.Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: a meta-analysis of randomized trials[J].Blood Press,2023,32(1):2242501.[15]Ku E,Del Vecchio L,Eckardt KU,et al.Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J].Kidney Int,2023,104(4):655-680.[16]Io H,Muto M,Sasaki Y,et al.Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease,retrospective longitudinal cohort study[J].BMC Nephrol,2023,24(1):74[17]Cianciaruso B,Ravani P,Barrett BJ,et al.Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease[J].J Nephrol,2008,21(6):861-870.[18]Wu Z,Shi M,Wang L,et al.Identification of Major Risk Factors and Non-linear Effects to the Development of Left Ventricular Hypertrophy in Chronic Kidney Disease by Constructing and Validation of Nomograms[J].Front Med (Lausanne),2022,9:914800.[19]Zhang Y,Peng G,Leng W,et al.Association between serum β2-microglobulin and left ventricular hypertrophy in patients with type 2 diabetes mellitus: A cross-sectional study[J].J Diabetes,2024,16(8):e13599.[20]Shen Y,Chen JJ,Yao WB,et al.Predictive value of serum β2-microglobulin in cardiac valve calcification in maintenance hemodialysis patients[J].J Thorac Dis,2023,15(9):4914-4924.[21]Wilson AM,Kimura E,Harada RK,et al.Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies[J].Circulation,2007,116(12):1396-13403.[22]You L,Xie R,Hu H,et al.High levels of serum β2-microglobulin predict severity of coronary artery disease[J].BMC Cardiovasc Disord,2017,17(1):71.[23]Zhang B,Chen X,Mu X,et al.Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation[J].Med Sci Monit,2021,27:e932813.[24]Brioschi M,Gianazza E,Agostoni P,et al.Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure[J].Int J Mol Sci,2021,22(2):838.

相似文献/References:

[1]谢 琴.肾小球C4d沉积在慢性肾病早期诊断及预后的价值分析[J].医学信息,2018,31(08):81.[doi:10.3969/j.issn.1006-1959.2018.08.025]
　XIE Qin.Value of Glomerular C4d Deposition in Early Diagnosis and Prognosis of Chronic Kidney Disease[J].Journal of Medical Information,2018,31(18):81.[doi:10.3969/j.issn.1006-1959.2018.08.025]
[2]钟 旭.慢性肾脏病相关神经精神疾病的研究[J].医学信息,2022,35(11):51.[doi:10.3969/j.issn.1006-1959.2022.11.015]
　ZHONG Xu.Study on Neuropsychiatric Diseases Associated with Chronic Kidney Disease[J].Journal of Medical Information,2022,35(18):51.[doi:10.3969/j.issn.1006-1959.2022.11.015]
[3]彭琪彦.慢性肾脏病患者RBP与T淋巴细胞亚群 检测的临床意义[J].医学信息,2019,32(18):91.[doi:10.3969/j.issn.1006-1959.2019.18.029]
　PENG Qi-yan.Clinical Significance of Detection of RBP and T Lymphocyte Subsets in Patients with Chronic Kidney Disease[J].Journal of Medical Information,2019,32(18):91.[doi:10.3969/j.issn.1006-1959.2019.18.029]
[4]徐海红,刘 宇,宋桂云.腹膜透析患者认知功能障碍对日常透析操作影响的研究[J].医学信息,2022,35(15):110.[doi:10.3969/j.issn.1006-1959.2022.15.025]
　XU Hai-hong,LIU Yu,SONG Gui-yun.Study on the Effect of Cognitive Dysfunction in Peritoneal Dialysis Patients on Daily Dialysis Operation[J].Journal of Medical Information,2022,35(18):110.[doi:10.3969/j.issn.1006-1959.2022.15.025]
[5]崔方强.足细胞上皮间质转分化研究[J].医学信息,2019,32(22):21.[doi:10.3969/j.issn.1006-1959.2019.22.008]
　CUI Fang-qiang.Epithelial Transdifferentiation of Podocytes[J].Journal of Medical Information,2019,32(18):21.[doi:10.3969/j.issn.1006-1959.2019.22.008]
[6]高 彬,孙 娜,常文秀.慢性肾脏病患者血钾异常相关因素分析[J].医学信息,2019,32(22):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
　GAO Bin,SUN Na,CHANG Wen-xiu.Analysis of Related Factors of Serum Potassium Abnormality in Patients with Chronic Kidney Disease[J].Journal of Medical Information,2019,32(18):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
[7]宋瑞龙,卢 斐,黄艳莉.复方硫酸亚铁叶酸片联合促红细胞生成素治疗肾性贫血的疗效[J].医学信息,2019,32(24):145.[doi:10.3969/j.issn.1006-1959.2019.24.052]
　SONG Rui-long,LU Fei,HUANG Yan-li.Efficacy of Compound Ferrous Sulfate Folic Acid Tablets Combined with Erythropoietin in the Treatment of Renal Anemia[J].Journal of Medical Information,2019,32(18):145.[doi:10.3969/j.issn.1006-1959.2019.24.052]
[8]王希敏.2型糖尿病并发慢性肾脏病患者外周血T淋巴细胞亚群变化与肾血管内皮功能障碍的相关 分析[J].医学信息,2021,34(23):77.[doi:10.3969/j.issn.1006-1959.2021.23.021]
　WANG Xi-min.Correlation Analysis of T Lymphocyte Subsets in Peripheral Blood with Renal Vascular Endothelial Dysfunction in Patients with Type 2 Diabetes Mellitus Complicated with Chronic Kidney Disease[J].Journal of Medical Information,2021,34(18):77.[doi:10.3969/j.issn.1006-1959.2021.23.021]
[9]袁 娟,赫英龙.参芎葡萄糖与前列地尔治疗慢性肾脏病的疗效比较[J].医学信息,2020,33(14):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
　YUAN Juan,HE Ying-long.Comparison of Curative Effect between Shenqiong Glucose and Alprostadil in Treating Chronic Kidney Disease[J].Journal of Medical Information,2020,33(18):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
[10]倪 曼.非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较[J].医学信息,2020,33(15):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
　NI Man.Comparison of the Efficacy of Febuxostat Tablets and Allopurinol in the Treatment of Chronic Kidney Disease with Hyperuricemia[J].Journal of Medical Information,2020,33(18):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]

更新日期/Last Update: 1900-01-01